title: Combination of Panaxadiol and Panaxatriol Type Saponins and Ophioponins From Shenmai Formula Attenuates Lipopolysaccharide-induced Inflammatory Injury in Cardiac Microvascular Endothelial Cells by Blocking NF-kappa B Pathway.
abstract: Vascular inflammatory injury leads to vascular endothelial dysfunction, thereby resulting in a variety of cardiovascular diseases (CVDs). Thus, attenuating vascular inflammatory injury has great significance for the prevention and treatment of CVDs. In China, Shenmai formula, a well-known ancient Chinese prescription, has been widely used to treat CVDs, such as coronary atherosclerosis and viral myocarditis. In vivo study has demonstrated that the optimal combination of 3 major active components from Shenmai formula, panaxadiol and panaxatriol type saponins and ophioponins, in a ratio of 1:2:2 might exert significant cardioprotective effects and anti-inflammatory activities. The aim of this study was to investigate whether the combination may exert anti-inflammatory effects on lipopolysaccharide-induced inflammatory injury in cardiac microvascular endothelial cells by blocking nuclear factor-kappa B (NF-κB) pathway. We found that the combination could exert anti-inflammatory effects by inhibiting the mRNA and protein expression of interleukin-1, interleukin-6, tumor necrosis factor alpha, and intercellular adhesion molecule, as well as reducing the lactate dehydrogenase content in lipopolysaccharide-injured cardiac microvascular endothelial cells supernatant. Further experiments showed that the combination could suppress the NF-κB p65 expression and IκBα phosphorylation in these cells. These findings suggested that the combination inhibits vascular inflammatory injury by blocking NF-κB pathway, which proves a new molecular mechanism of the Shenmai formula to treat CVDs.
authors.affiliation: *Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; †Key Laboratory of Formula of Traditional Chinese Medicine (Tianjin University of Traditional Chinese Medicine), Ministry of Education, Tianjin, China; ‡Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; and §School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
authors.forename: Jinqiang
authors.initials: J
authors.lastname: Zhu
authors.forename: Yubin
authors.initials: Y
authors.lastname: Liang
authors.forename: Shaoqian
authors.initials: S
authors.lastname: Yue
authors.forename: Guanwei
authors.initials: G
authors.lastname: Fan
authors.forename: Han
authors.initials: H
authors.lastname: Zhang
authors.forename: Meng
authors.initials: M
authors.lastname: Zhang
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D036145:Ginsenosides / Q000008:administration & dosage*; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity; D055806:Microvessels / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D031441:Ophiopogon; D051381:Rats; D017208:Rats, Wistar; D012503:Saponins / Q000008:administration & dosage; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D036145:Ginsenosides; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D016328:NF-kappa B; D012503:Saponins; C009252:fructus schizandrae, radix ginseng, radix ophiopogonis drug combination; C004564:panaxadiol; C004563:panaxatriol